PMID- 37448181 OWN - NLM STAT- Publisher LR - 20231014 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 44 IP - 39 DP - 2023 Oct 14 TI - Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table. PG - 4141-4156 LID - 10.1093/eurheartj/ehad445 [doi] AB - Metabolic comorbidities are common in patients with cardiorenal disease; they can cause atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect prognosis. Common comorbidities are Type 2 diabetes mellitus (T2DM), obesity/overweight, chronic kidney disease (CKD), and chronic liver disease. The cardiovascular system, kidneys, and liver are linked to many of the same risk factors (e.g. dyslipidaemia, hypertension, tobacco use, diabetes, and central/truncal obesity), and shared metabolic and functional abnormalities lead to damage throughout these organs via overlapping pathophysiological pathways. The COVID-19 pandemic has further complicated the management of cardiometabolic diseases. Obesity, T2DM, CKD, and liver disease are associated with increased risk of poor outcomes of COVID-19 infection, and conversely, COVID-19 can lead to worsening of pre-existing ASCVD. The high rates of these comorbidities highlight the need to improve recognition and treatment of ASCVD in patients with obesity, insulin resistance or T2DM, chronic liver diseases, and CKD and equally, to improve recognition and treatment of these diseases in patients with ASCVD. Strategies to prevent and manage cardiometabolic diseases include lifestyle modification, pharmacotherapy, and surgery. There is a need for more programmes at the societal level to encourage a healthy diet and physical activity. Many pharmacotherapies offer mechanism-based approaches that can target multiple pathophysiological pathways across diseases. These include sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, selective mineralocorticoid receptor antagonists, and combined glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist. Non-surgical and surgical weight loss strategies can improve cardiometabolic disorders in individuals living with obesity. New biomarkers under investigation may help in the early identification of individuals at risk and reveal new treatment targets. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Cosentino, Francesco AU - Cosentino F AUID- ORCID: 0000-0002-6967-5685 AD - Cardiology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden. FAU - Verma, Subodh AU - Verma S AD - Division of Cardiac Surgery, St Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada. FAU - Ambery, Philip AU - Ambery P AD - Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. FAU - Treppendahl, Marianne Bach AU - Treppendahl MB AD - Cardiovascular Diseases, Global Medical Affairs, Novo Nordisk A/S, Soborg, Denmark. FAU - van Eickels, Martin AU - van Eickels M AD - Thrombosis & Hematology, Medical Affairs, Bayer AG, Berlin, Germany. FAU - Anker, Stefan D AU - Anker SD AD - Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), and German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charite Universitatsmedizin, Berlin, Germany. FAU - Cecchini, Michele AU - Cecchini M AD - Health Division, Organisation for Economic Co-operation and Development (OECD), Paris, France. FAU - Fioretto, Paola AU - Fioretto P AD - Department of Medicine, University of Padova, Padova, Italy. FAU - Groop, Per-Henrik AU - Groop PH AUID- ORCID: 0000-0003-4055-6954 AD - Department of Nephrology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland. AD - Folkhalsan Institute of Genetics, Helsinki, Finland. AD - Department of Diabetes, Monash University, Melbourne, Australia. FAU - Hess, David AU - Hess D AD - Department of Physiology and Pharmacology, University of Western Ontario, Robarts Research Institute, London, ON, Canada. AD - Department of Pharmacology, University of Toronto, Division of Vascular Surgery, St Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada. FAU - Khunti, Kamlesh AU - Khunti K AD - Leicester Diabetes Centre, University of Leicester, Leicester, UK. FAU - Lam, Carolyn S P AU - Lam CSP AUID- ORCID: 0000-0003-1903-0018 AD - National Heart Centre Singapore, Duke-National University of Singapore, Singapore. FAU - Richard-Lordereau, Isabelle AU - Richard-Lordereau I AD - General Medicine Europe, Amgen Europe, Rotkreutz ZG, Switzerland. FAU - Lund, Lars H AU - Lund LH AUID- ORCID: 0000-0003-1411-4482 AD - Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. FAU - McGreavy, Paul AU - McGreavy P AUID- ORCID: 0000-0001-8651-9476 AD - ESC Patients Forum, Sheffield, UK. FAU - Newsome, Philip N AU - Newsome PN AD - National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. AD - Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. FAU - Sattar, Naveed AU - Sattar N AUID- ORCID: 0000-0002-1604-2593 AD - School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. FAU - Solomon, Scott AU - Solomon S AD - Harvard Medical School, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. FAU - Weidinger, Franz AU - Weidinger F AD - 2nd Medical Department with Cardiology and Intensive Care Medicine, Klinik Landstrasse, Vienna, Austria. FAU - Zannad, Faiez AU - Zannad F AUID- ORCID: 0000-0001-7456-1570 AD - Universite de Lorraine, Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy, Nancy, France. FAU - Zeiher, Andreas AU - Zeiher A AD - Cardio Pulmonary Institute, Goethe University of Frankfurt, Frankfurt, Germany. LA - eng PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM OTO - NOTNLM OT - Atherosclerotic cardiovascular disease OT - Bariatric surgery OT - COVID-19 OT - Cardiometabolic risk factors OT - Chronic kidney disease OT - Chronic liver diseases OT - Glucagon-like peptide-1 receptor agonists OT - Obesity OT - Sodium glucose cotransporter-2 inhibitors OT - Type 2 diabetes mellitus EDAT- 2023/07/14 13:06 MHDA- 2023/07/14 13:06 CRDT- 2023/07/14 02:16 PHST- 2022/12/20 00:00 [received] PHST- 2023/04/24 00:00 [revised] PHST- 2023/06/28 00:00 [accepted] PHST- 2023/07/14 13:06 [pubmed] PHST- 2023/07/14 13:06 [medline] PHST- 2023/07/14 02:16 [entrez] AID - 7224026 [pii] AID - 10.1093/eurheartj/ehad445 [doi] PST - ppublish SO - Eur Heart J. 2023 Oct 14;44(39):4141-4156. doi: 10.1093/eurheartj/ehad445.